UCB Looks To Bolster Its Epilepsy Pipeline With Neurona Buyout

 
• By Joseph Haas
  
UCB makes its third epilepsy-related acquisition this decade (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deal Watch

More from Deals